CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
ranolazinedrug
Likely dose
ranolazine 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02360397
NCT02360397Phase 2Completed
CompareCT.gov

Ranolazine Mediated Premature Ventricular Contraction Reduction in Ischemic Heart Disease

Kent Hospital, Rhode Island·interventional·Posted Feb 10, 2015·Updated Jan 29, 2020

In Brief

A Phase 2 clinical trial evaluating ranolazine for Ventricular Premature Complexes and Myocardial Ischemia. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether ranolazine has beneficial effects on cardiac ischemia through reduction of premature ventricular contraction burden.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVentricular Premature Complexes, Myocardial Ischemia
CountriesUnited States
CollaboratorsGilead Sciences

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 10, 2015
Enrollment StartDec 1, 2014
Primary CompletionDec 31, 2017
Study CompletionFeb 23, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.4 years ago

Interventions

ranolazinedrug

Ranolazine 1000 mg tablet twice daily for 30 days